Pierre-François Meyer1,2,3, Alexa Pichet Binette1,2,3, Julie Gonneaud1,2, John C S Breitner1,2,3,4, Sylvia Villeneuve1,2,3,4. 1. Douglas Mental Health University Institute, Studies on Prevention of Alzheimer's Disease Centre, Montreal, Quebec, Canada. 2. Department of Psychiatry, McGill University, Montreal, Quebec, Canada. 3. McGill Centre for Integrative Neuroscience, McGill University, Montreal, Quebec, Canada. 4. Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.
Abstract
Importance: Fluid and imaging biomarkers of Alzheimer disease (AD) are often used interchangeably, but some biomarkers may reveal earlier stages of disease. Objective: To characterize individuals with tau abnormality indicated by cerebrospinal fluid (CSF) assay or positron emission tomography (PET). Design, Setting, and Participants: Between 2010 and 2019, 322 participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI) underwent CSF and PET assessments of tau pathology. Data-driven, clinically relevant thresholds for CSF phosphorylated tau (P-tau) (≥26.64 pg/mL) and flortaucipir-PET meta-regions of interest (ROI) (standard uptake value ratio ≥1.37) indicated participants' tau status as CSF-/PET-, CSF+/PET-, CSF-/PET+, and CSF+/PET+. Of 1659 ADNI participants with a CSF or flortaucipir assessment, 588 had both measures (1071 were excluded). Among these, 266 were further excluded because they did not have flortaucipir and CSF testing within less than 25 months, leaving 322 for analysis. Of these, 213 were cognitively unimpaired (CU); 98 had mild cognitive impairment (MCI); and 11 had AD dementia. Main Outcomes and Measures: We compared tau-positive vs tau-negative groups as indicated by either modality or demographic and clinical variables, amyloid β-PET burden, and flortaucipir-PET binding across Braak stage-related ROIs. We also compared 5-year rates of CSF P-tau accumulation and cognitive decline prior to flortaucipir-PET scanning. Results: Among the 322 study participants, 180 were women (56%), and the mean (SD) age was 73.08 (7.37) years. Two hundred ten participants were CSF-/PET- (65%); 63 were CSF+/PET- (19.5%); 15 were CSF-/PET+ (4.6%); and 34 were CSF+/PET+ (10.5%). Most CSF-/PET+ participants had measures near CSF or PET tau thresholds. The CSF+/PET- participants showed faster 5-year accrual of P-tau and increased flortaucipir-PET binding in early Braak ROIs but similar memory decline compared with CSF-/PET- participants. Tau-positive individuals by either measure showed increased amyloid β-PET burden. All CSF+/PET+ individuals were amyloid-positive, and 26 had MCI or AD dementia (76%). Compared with the CSF-/PET- group, CSF+/PET+ individuals had experienced faster 5-year accrual of CSF P-tau and decline in memory and executive function, resulting in reduced cognitive abilities at the time of flortaucipir-PET assessment. Conclusions and Relevance: Suprathreshold CSF P-tau without flortaucipir-PET abnormality may indicate a stage of AD development characterized by early tau abnormality without measurable loss in cognitive performance. Persons with both tau CSF and PET abnormality appear to have reduced cognitive capacities resulting from faster antecedent cognitive decline. Elevation of CSF P-tau appears to precede flortaucipir-PET positivity in the progression of AD pathogenesis and related cognitive decline.
Importance: Fluid and imaging biomarkers of Alzheimer disease (AD) are often used interchangeably, but some biomarkers may reveal earlier stages of disease. Objective: To characterize individuals with tau abnormality indicated by cerebrospinal fluid (CSF) assay or positron emission tomography (PET). Design, Setting, and Participants: Between 2010 and 2019, 322 participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI) underwent CSF and PET assessments of tau pathology. Data-driven, clinically relevant thresholds for CSF phosphorylated tau (P-tau) (≥26.64 pg/mL) and flortaucipir-PET meta-regions of interest (ROI) (standard uptake value ratio ≥1.37) indicated participants' tau status as CSF-/PET-, CSF+/PET-, CSF-/PET+, and CSF+/PET+. Of 1659 ADNI participants with a CSF or flortaucipir assessment, 588 had both measures (1071 were excluded). Among these, 266 were further excluded because they did not have flortaucipir and CSF testing within less than 25 months, leaving 322 for analysis. Of these, 213 were cognitively unimpaired (CU); 98 had mild cognitive impairment (MCI); and 11 had AD dementia. Main Outcomes and Measures: We compared tau-positive vs tau-negative groups as indicated by either modality or demographic and clinical variables, amyloid β-PET burden, and flortaucipir-PET binding across Braak stage-related ROIs. We also compared 5-year rates of CSF P-tau accumulation and cognitive decline prior to flortaucipir-PET scanning. Results: Among the 322 study participants, 180 were women (56%), and the mean (SD) age was 73.08 (7.37) years. Two hundred ten participants were CSF-/PET- (65%); 63 were CSF+/PET- (19.5%); 15 were CSF-/PET+ (4.6%); and 34 were CSF+/PET+ (10.5%). Most CSF-/PET+ participants had measures near CSF or PET tau thresholds. The CSF+/PET- participants showed faster 5-year accrual of P-tau and increased flortaucipir-PET binding in early Braak ROIs but similar memory decline compared with CSF-/PET- participants. Tau-positive individuals by either measure showed increased amyloid β-PET burden. All CSF+/PET+ individuals were amyloid-positive, and 26 had MCI or AD dementia (76%). Compared with the CSF-/PET- group, CSF+/PET+ individuals had experienced faster 5-year accrual of CSF P-tau and decline in memory and executive function, resulting in reduced cognitive abilities at the time of flortaucipir-PET assessment. Conclusions and Relevance: Suprathreshold CSF P-tau without flortaucipir-PET abnormality may indicate a stage of AD development characterized by early tau abnormality without measurable loss in cognitive performance. Persons with both tau CSF and PET abnormality appear to have reduced cognitive capacities resulting from faster antecedent cognitive decline. Elevation of CSF P-tau appears to precede flortaucipir-PET positivity in the progression of AD pathogenesis and related cognitive decline.
Authors: Paul K Crane; Adam Carle; Laura E Gibbons; Philip Insel; R Scott Mackin; Alden Gross; Richard N Jones; Shubhabrata Mukherjee; S McKay Curtis; Danielle Harvey; Michael Weiner; Dan Mungas Journal: Brain Imaging Behav Date: 2012-12 Impact factor: 3.978
Authors: Laura E Gibbons; Adam C Carle; R Scott Mackin; Danielle Harvey; Shubhabrata Mukherjee; Philip Insel; S McKay Curtis; Dan Mungas; Paul K Crane Journal: Brain Imaging Behav Date: 2012-12 Impact factor: 3.978
Authors: Abhinay D Joshi; Michael J Pontecorvo; Chrisopher M Clark; Alan P Carpenter; Danna L Jennings; Carl H Sadowsky; Lee P Adler; Karel D Kovnat; John P Seibyl; Anupa Arora; Krishnendu Saha; Jason D Burns; Mark J Lowrey; Mark A Mintun; Daniel M Skovronsky Journal: J Nucl Med Date: 2012-02-13 Impact factor: 10.057
Authors: Anne M Fagan; Chengjie Xiong; Mateusz S Jasielec; Randall J Bateman; Alison M Goate; Tammie L S Benzinger; Bernardino Ghetti; Ralph N Martins; Colin L Masters; Richard Mayeux; John M Ringman; Martin N Rossor; Stephen Salloway; Peter R Schofield; Reisa A Sperling; Daniel Marcus; Nigel J Cairns; Virginia D Buckles; Jack H Ladenson; John C Morris; David M Holtzman Journal: Sci Transl Med Date: 2014-03-05 Impact factor: 17.956
Authors: Randall J Bateman; Chengjie Xiong; Tammie L S Benzinger; Anne M Fagan; Alison Goate; Nick C Fox; Daniel S Marcus; Nigel J Cairns; Xianyun Xie; Tyler M Blazey; David M Holtzman; Anna Santacruz; Virginia Buckles; Angela Oliver; Krista Moulder; Paul S Aisen; Bernardino Ghetti; William E Klunk; Eric McDade; Ralph N Martins; Colin L Masters; Richard Mayeux; John M Ringman; Martin N Rossor; Peter R Schofield; Reisa A Sperling; Stephen Salloway; John C Morris Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Jasmeer P Chhatwal; Aaron P Schultz; Gad A Marshall; Brendon Boot; Teresa Gomez-Isla; Julien Dumurgier; Molly LaPoint; Clemens Scherzer; Allyson D Roe; Bradley T Hyman; Reisa A Sperling; Keith A Johnson Journal: Neurology Date: 2016-07-29 Impact factor: 9.910
Authors: Sebastian Palmqvist; Michael Schöll; Olof Strandberg; Niklas Mattsson; Erik Stomrud; Henrik Zetterberg; Kaj Blennow; Susan Landau; William Jagust; Oskar Hansson Journal: Nat Commun Date: 2017-10-31 Impact factor: 14.919
Authors: Alexandra N Trelle; Valerie A Carr; Edward N Wilson; Michelle S Swarovski; Madison P Hunt; Tyler N Toueg; Tammy T Tran; Divya Channappa; Nicole K Corso; Monica K Thieu; Manasi Jayakumar; Ayesha Nadiadwala; Wanjia Guo; Natalie J Tanner; Jeffrey D Bernstein; Celia P Litovsky; Scott A Guerin; Anna M Khazenzon; Marc B Harrison; Brian K Rutt; Gayle K Deutsch; Frederick T Chin; Guido A Davidzon; Jacob N Hall; Sharon J Sha; Carolyn A Fredericks; Katrin I Andreasson; Geoffrey A Kerchner; Anthony D Wagner; Elizabeth C Mormino Journal: Neurology Date: 2021-01-06 Impact factor: 9.910
Authors: Daniel Ferreira; Scott A Przybelski; Timothy G Lesnick; Afina W Lemstra; Elisabet Londos; Frederic Blanc; Zuzana Nedelska; Christopher G Schwarz; Jonathan Graff-Radford; Matthew L Senjem; Julie A Fields; David S Knopman; Rodolfo Savica; Tanis J Ferman; Neill R Graff-Radford; Val J Lowe; Clifford R Jack; Ronald C Petersen; Brit Mollenhauer; Sara Garcia-Ptacek; Carla Abdelnour; Jakub Hort; Laura Bonanni; Ketil Oppedal; Milica G Kramberger; Bradley F Boeve; Dag Aarsland; Eric Westman; Kejal Kantarci Journal: Neurology Date: 2020-09-28 Impact factor: 9.910
Authors: Rik Ossenkoppele; Juhan Reimand; Ruben Smith; Antoine Leuzy; Olof Strandberg; Sebastian Palmqvist; Erik Stomrud; Henrik Zetterberg; Philip Scheltens; Jeffrey L Dage; Femke Bouwman; Kaj Blennow; Niklas Mattsson-Carlgren; Shorena Janelidze; Oskar Hansson Journal: EMBO Mol Med Date: 2021-07-13 Impact factor: 12.137